204 related articles for article (PubMed ID: 35859155)
1. Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup.
Martinez-Monleon A; Kryh Öberg H; Gaarder J; Berbegall AP; Javanmardi N; Djos A; Ussowicz M; Taschner-Mandl S; Ambros IM; Øra I; Sandstedt B; Beiske K; Ladenstein R; Noguera R; Ambros PF; Gordon Murkes L; Ljungman G; Kogner P; Fransson S; Martinsson T
Sci Rep; 2022 Jul; 12(1):12420. PubMed ID: 35859155
[TBL] [Abstract][Full Text] [Related]
2. Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients.
Amoroso L; Ognibene M; Morini M; Conte M; Di Cataldo A; Tondo A; D'Angelo P; Castellano A; Garaventa A; Lasorsa VA; Podestà M; Capasso M; Pezzolo A
Genes Chromosomes Cancer; 2020 May; 59(5):277-285. PubMed ID: 31756773
[TBL] [Abstract][Full Text] [Related]
3. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
Gamble LD; Kees UR; Tweddle DA; Lunec J
Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
[TBL] [Abstract][Full Text] [Related]
4. CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.
Gogolin S; Ehemann V; Becker G; Brueckner LM; Dreidax D; Bannert S; Nolte I; Savelyeva L; Bell E; Westermann F
Cell Cycle; 2013 Apr; 12(7):1091-104. PubMed ID: 23462184
[TBL] [Abstract][Full Text] [Related]
5. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.
Italiano A; Bianchini L; Gjernes E; Keslair F; Ranchere-Vince D; Dumollard JM; Haudebourg J; Leroux A; Mainguené C; Terrier P; Chibon F; Coindre JM; Pedeutour F
Clin Cancer Res; 2009 Sep; 15(18):5696-703. PubMed ID: 19737942
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.
He J; Gu L; Zhang H; Zhou M
Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876
[TBL] [Abstract][Full Text] [Related]
7. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
[TBL] [Abstract][Full Text] [Related]
8. MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas.
Grünewald I; Trautmann M; Busch A; Bauer L; Huss S; Schweinshaupt P; Vollbrecht C; Odenthal M; Quaas A; Büttner R; Meyer MF; Beutner D; Hüttenbrink KB; Wardelmann E; Stenner M; Hartmann W
Oncotarget; 2016 Nov; 7(46):75261-75272. PubMed ID: 27662657
[TBL] [Abstract][Full Text] [Related]
9. Combined targeting of the p53 and pRb pathway in neuroblastoma does not lead to synergistic responses.
Schubert NA; Schild L; van Oirschot S; Keller KM; Alles LK; Vernooij L; Nulle ME; Dolman MEM; van den Boogaard ML; Molenaar JJ
Eur J Cancer; 2021 Jan; 142():1-9. PubMed ID: 33190064
[TBL] [Abstract][Full Text] [Related]
10. Detection of MDM2/CDK4 amplification in lipomatous soft tissue tumors from formalin-fixed, paraffin-embedded tissue: comparison of multiplex ligation-dependent probe amplification (MLPA) and fluorescence in situ hybridization (FISH).
Creytens D; van Gorp J; Ferdinande L; Speel EJ; Libbrecht L
Appl Immunohistochem Mol Morphol; 2015 Feb; 23(2):126-33. PubMed ID: 25679065
[TBL] [Abstract][Full Text] [Related]
11. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma.
Mejia-Guerrero S; Quejada M; Gokgoz N; Gill M; Parkes RK; Wunder JS; Andrulis IL
Genes Chromosomes Cancer; 2010 Jun; 49(6):518-25. PubMed ID: 20196171
[TBL] [Abstract][Full Text] [Related]
13. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM
Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205
[TBL] [Abstract][Full Text] [Related]
14. CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus.
Hernández L; Beà S; Pinyol M; Ott G; Katzenberger T; Rosenwald A; Bosch F; López-Guillermo A; Delabie J; Colomer D; Montserrat E; Campo E
Cancer Res; 2005 Mar; 65(6):2199-206. PubMed ID: 15781632
[TBL] [Abstract][Full Text] [Related]
15. CDK4 inhibition diminishes p53 activation by MDM2 antagonists.
Sriraman A; Dickmanns A; Najafova Z; Johnsen SA; Dobbelstein M
Cell Death Dis; 2018 Sep; 9(9):918. PubMed ID: 30206211
[TBL] [Abstract][Full Text] [Related]
16. Amplification of CDK4 and MDM2 in malignant melanoma.
Muthusamy V; Hobbs C; Nogueira C; Cordon-Cardo C; McKee PH; Chin L; Bosenberg MW
Genes Chromosomes Cancer; 2006 May; 45(5):447-54. PubMed ID: 16419059
[TBL] [Abstract][Full Text] [Related]
17. High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: A cytogenomic microarray analysis of 47 cases.
Ricciotti RW; Baraff AJ; Jour G; Kyriss M; Wu Y; Liu Y; Li SC; Hoch B; Liu YJ
Cancer Genet; 2017 Dec; 218-219():69-80. PubMed ID: 29153098
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.
Van Maerken T; Speleman F; Vermeulen J; Lambertz I; De Clercq S; De Smet E; Yigit N; Coppens V; Philippé J; De Paepe A; Marine JC; Vandesompele J
Cancer Res; 2006 Oct; 66(19):9646-55. PubMed ID: 17018622
[TBL] [Abstract][Full Text] [Related]
19. Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review.
Assi T; Kattan J; Rassy E; Nassereddine H; Farhat F; Honore C; Le Cesne A; Adam J; Mir O
Crit Rev Oncol Hematol; 2020 Sep; 153():103029. PubMed ID: 32593094
[TBL] [Abstract][Full Text] [Related]
20. p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells.
Tweddle DA; Malcolm AJ; Cole M; Pearson AD; Lunec J
Am J Pathol; 2001 Jun; 158(6):2067-77. PubMed ID: 11395384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
